Main Industry
Biotechnology
Main Product/Service
In Vivo and In Vitro Antigen-Specific T-Cell Activation Platform
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2023
Unified Business No.
94131960
Status
Active
Number of Employees
4
Total Paid-in
Capital
6,994,500 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
MediTrex Bioscience INC. has pioneered a translational approach to increase the tumor antigen load of tumor-infiltrating lymphocyte (TIL) therapy by enabling dendritic cells (DCs) to select appropriate tumor antigens to trigger a robust TIL response. MediTrex Bioscience INC. believes that this in vivo and in vitro antigen-specific T-cell activation platform is of great significance for improving T-cell immunotherapies and cancer vaccines.
(The content above was translated by AI.)
(The content above was translated by AI.)
